MannKind reports Q2 non-GAAP EPS 5c, consensus 8c

Reports Q2 revenue $76.5M, consensus $78.78M. “The submission of our supplemental Biologics License Application for Afrezza in pediatric patients is a meaningful milestone for MannKind (MNKD) and people living with diabetes,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In our orphan lung pipeline, we’re encouraged by the robust enrollment progress in the ICoN-1 trial of inhaled clofazimine for NTM lung disease, and we are excited to advance nintedanib DPI into Phase 2 for IPF.”